Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines

British Journal of Haematology

Volumn 138, Issue 6, 2007, Pages 802-811

  Li, Xin ^a   Pennisi, Angela ^a   Zhan, Fenghuang ^a   Sawyer, Jeffrey R ^a   Shaughnessy, John D ^a   Yaccoby, Shmuel ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Bioluminescent imaging; Hyperdiploid myeloma; Myeloma cell lines

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CYTOMETRY; DIPLOIDY; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MOUSE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CYTOLOGICAL TECHNIQUES; DIPLOIDY; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; MICE; MICE, SCID; MODELS, ANIMAL; MULTIPLE MYELOMA; PYRAZINES;

EID: 34548168002     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06742.x     Document Type: Article

References (39)

1. Abbaszadegan, M.R., Foley, N.E., Gleason-Guzman, M.C. Dalton, W.S. (1996) Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. International Journal of Cancer, 66, 506 514.
2. Akiyama, M., Hideshima, T., Hayashi, T., Tai, Y.T., Mitsiades, C.S., MItsiades, N., Chauhan, D., Richardson, P., Munshi, N.C. Anderson, K.C. (2002) Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Research, 62, 3876 3882.
3. Bataille, R., Klein, B., Jourdan, M., Rossi, J.F. Durie, B.G. (1989) Spontaneous secretion of tumor necrosis factor-beta by human myeloma cell lines. Cancer, 63, 877 880.
4. Bergsagel, P.L. Kuehl, W.M. (2001) Chromosome translocations in multiple myeloma. Oncogene, 20, 5611 5622.
5. Bergsagel, P.L. Kuehl, W.M. (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology, 23, 6333 6338.
6. Bergsagel, P.L., Kuehl, W.M., Zhan, F., Sawyer, J., Barlogie, B. Shaughnessy, Jr., J. (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood, 106, 296 303.
7. bes-Marun, C.S., Dewald, G.W., Bryant, S., Picken, E., Santana-Davila, R., Gonzalez-Paz, N., Winkler, J.M., Kyle, R.A., Gertz, M.A., Witzig, T.E., Dispenzieri, A., Lacy, M.Q., Rajkumar, S.V., Lust, J.A., Greipp, P.R. Fonseca, R. (2003) Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia, 17, 427 436.
8. Billadeau, D., Liu, P., Jelinek, D., Shah, N., LeBien, T.W. Van Ness, B. (1997) Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Research, 57, 2268 2275.
9. Chesi, M., Nardini, E., Brents, L.A., Schrock, E., Ried, T., Kuehl, W.M. Bergsagel, P.L. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics, 16, 260 264.
10. Chng, W.J., Kumar, S., Vanwier, S., Ahmann, G., Price-Troska, T., Henderson, K., Chung, T.H., Kim, S., Mulligan, G., Bryant, B., Carpten, J., Gertz, M., Rajkumar, S.V., Lacy, M., Dispenzieri, A., Kyle, R., Greipp, P., Bergsagel, P.L. Fonseca, R. (2007) Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Research, 67, 2982 2989.
11. Croonquist, P.A., Linden, M.A., Zhao, F. Van Ness, B.G. (2003) Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood, 102, 2581 2592.
12. De Vos, J., Couderc, G., Tarte, K., Jourdan, M., Requirand, G., Delteil, M.C., Rossi, J.F., Mechti, N. Klein, B. (2001) Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood, 98, 771 780.
13. Fonseca, R., bes-Marun, C.S., Picken, E.B., Dewald, G.W., Bryant, S.C., Winkler, J.M., Blood, E., Oken, M.M., Santana-Davila, R., Gonzalez-Paz, N., Kyle, R.A., Gertz, M.A., Dispenzieri, A., Lacy, M.Q. Greipp, P.R. (2003) The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood, 102, 2562 2567.
14. Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P.L., Chesi, M., Davies, F.E., Drach, J., Greipp, P.R., Kirsch, I.R., Kuehl, W.M., Hernandez, J.M., Minvielle, S., Pilarski, L.M., Shaughnessy, Jr., J.D., Stewart, A.K. Avet-Loiseau, H. (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research, 64, 1546 1558.
15. Ge, Y., Zhan, F., Barlogie, B., Epstein, J., Shaughnessy, J. Yaccoby, Y. (2006) Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. British Journal of Haematology, 133, 83 92.
16. Hallek, M., Bergsagel, P.L. Anderson, K.C. (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 3 21.
17. Hazlehurst, L.A., Enkemann, S.A., Beam, C.A., Argilagos, R.F., Painter, J., Shain, K.H., Saporta, S., Boulware, D., Moscinski, L., Alsina, M. Dalton, W.S. (2003) Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Research, 63, 7900 7906.
18. Hideshima, T., Chauhan, D., Hayashi, T., Akiyama, M., Mitsiades, N., Mitsiades, C., Podar, K., Munshi, N.C., Richardson, P.G. Anderson, K.C. (2003) Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene, 22, 8386 8393.
19. Latreille, J., Barlogie, B., Dosik, G., Johnston, D.A., Drewinko, B. Alexanian, R. (1980) Cellular DNA content as a marker of human multiple myeloma. Blood, 55, 403 408.
20. LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P.G., Munshi, N.C. Anderson, K.C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62, 4996 5000.
21. Mazars, G.R., Portier, M., Zhang, X.G., Jourdan, M., Bataille, R., Theillet, C. Klein, B. (1992) Mutations of the p53 gene in human myeloma cell lines. Oncogene, 7, 1015 1018.
22. Mitsiades, C.S., Mitsiades, N.S., Bronson, R.T., Chauhan, D., Munshi, N., Treon, S.P., Maxwell, C.A., Pilarski, L., Hideshima, T., Hoffman, R.M. Anderson, K.C. (2003) Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Research, 63, 6689 6696.
23. Miyashita, E.M., Yang, B., Lam, K.M., Crawford, D.H. Thorley-Lawson, D.A. (1995) A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell, 80, 593 601.
24. Sawyer, J.R., Lukacs, J.L., Thomas, E.L., Swanson, C.M., Goosen, L.S., Sammartino, G., Gilliland, J.C., Munshi, N.C., Tricot, G., Shaughnessy, Jr., J.D. Barlogie, B. (2001) Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. British Journal of Haematology, 112, 167 174.
25. Smadja, N.V., Fruchart, C., Isnard, F., Louvet, C., Dutel, J.L., Cheron, N., Grange, M.J., Monconduit, M. Bastard, C. (1998) Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia, 12, 960 969.
26. Smadja, N.V., Bastard, C., Brigaudeau, C., Leroux, D. Fruchart, C. (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood, 98, 2229 2238.
27. Tassone, P., Neri, P., Carrasco, D.R., Burger, R., Goldmacher, V.S., Fram, R., Munshi, V., Shammas, M.A., Catley, L., Jacob, G.S., Venuta, S., Anderson, K.C. Munshi, N.C. (2005) A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood, 106, 713 716.
28. Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B. Shaughnessy, Jr., J.D. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine, 349, 2483 2494.
29. Verdelli, D., Mattioli, M., Fabris, S., Nobili, L., Intini, D., Guerneri, S., Todoerti, K., Zanella, A., Deliliers, G.L., Lombardi, L. Neri, A. (2005) Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines. Haematologica, 90, 1541 1548.
30. Yaccoby, S. (2005) The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clinical Cancer Research, 11, 7599 7606.
31. Yaccoby, S. Epstein, J. (1999) The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood, 94, 3576 3582.
32. Yaccoby, S., Barlogie, B. Epstein, J. (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood, 92, 2908 2913.
33. Yaccoby, S., Johnson, C.L., Mahaffey, S.C., Wezeman, M.J., Barlogie, B. Epstein, J. (2002a) Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood, 100, 4162 4168.
34. Yaccoby, S., Pearse, R.N., Johnson, C.L., Barlogie, B., Choi, Y. Epstein, J. (2002b) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British Journal of Haematology, 116, 278 290.
35. Yaccoby, S., Wezeman, M.J., Zangari, M., Walker, R., Cottler-Fox, M., Gaddy, D., Ling, W., Saha, R., Barlogie, B., Tricot, G. Epstein, J. (2006) Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica, 91, 192 199.
36. Yaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B. Shaughnessy, Jr., J.D. (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 109, 2106 2111.
37. Yata, K. Yaccoby, S. (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia, 18, 1891 1897.
38. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. Shaughnessy, Jr., J. (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 99, 1745 1757.
39. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. Shaughnessy, Jr., J.D. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020 2028.